STAT+: Roche goes beyond licensing in deal with Chinese biotech

STAT+ reports that Roche has partnered with Chinese biotech company Defand Therapeutics to discover new medicines. The deal goes beyond licensing, with Roche providing funding and resources to Defand.

The partnership focuses on discovering and developing new therapies for cancer and other diseases.

Roche's investment in Defand is part of its strategy to expand its presence in the Chinese market and tap into the country's innovative biotech sector.

The deal also reflects the growing trend of international collaborations in the biotech industry.